Blacksmith Medicines, Inc. and Zoetis announced a collaboration to discover and develop novel antibiotics for animal health.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
158.4 USD | +3.30% | +8.14% | -19.73% |
Apr. 23 | Barclays Adjusts Zoetis' Price Target to $230 From $260, Keeps Overweight Rating | MT |
Apr. 22 | Jefferies Lowers Zoetis Price Target to $200 from $220 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.73% | 72.39B | |
-11.01% | 6.54B | |
+15.88% | 3.43B | |
-2.92% | 3.12B | |
-0.68% | 1.4B | |
-17.27% | 1.34B | |
-2.73% | 1.26B | |
-14.67% | 1.12B | |
-5.37% | 990M | |
-24.06% | 805M |
- Stock Market
- Equities
- ZTS Stock
- News Zoetis Inc.
- Blacksmith Medicines and Zoetis Announce Research Collaboration for Novel Animal Health Antibiotics